Keyword: Dupixent

A lot has changed in the severe asthma market lately—including the way GlaxoSmithKline is talking about its contender, Nucala.

The eye drug star has nabbed an FDA nod as a 12-week formulation in wet AMD and is expected to get into diabetic retinopathy next May.

Dupixent grew sales by 28% sequentially at constant currencies, to €225 million, and that doesn't even count a recent major approval in asthma.

Sanofi's Dupixent picked up its important asthma approval on Friday, setting the drug up for a multibillion-dollar peak sales boost.

Strong data for Dupixent in sinusitis could boost sales for Sanofi and Regeneron, but challenges abound, including payer pushback.

Xolair, Nucala, Cinqair, Fasenra and Dupixent will need to take a 50% to 68% discount off the list price to achieve cost-effectiveness, says ICER.

The new eczema data came a month ahead of an expected FDA decision on the drug's fate in asthma.

Only days after the FDA turned away Regeneron's Eylea for a label expansion, the drugmaker has secured the approval it sought.

What does severe eczema feel like? Sanofi and Regeneron's first Dupixent ads feature images—tiny crawling insects, for one—to illustrate just that.

As much as Sanofi has struggled with diabetes the past few years, it could typically count on vaccines and Genzyme—but not this quarter.